Shuktika Nandkeolyar, Tanya Doctorian, Gary Fraser, Rachel Ryu, Colleen Fearon, David Tryon, Whitney Kagabo, Dmitry Abramov, Christopher Hauschild, Liset Stoletniy, Anthony Hilliard, Antoine Sakr
BACKGROUND: Though controversial, the short-duration in-patient use of inotropes in cardiogenic shock (CS) remain an ACC/AHA Class IIa indication, and are frequently used in the initial treatment of CS. We evaluated in-patient mortality and effect on mortality risk of commonly used vasoactive inotropic medications for the medical management of SCAI stage B and C cardiogenic shock patients in a tertiary care cardiac care unit: dobutamine, dopamine, milrinone, and norepinephrine. METHODS: We retrospectively evaluated 342 patients who received dobutamine, milrinone, dopamine, norepinephrine or a combination of these medications for SCAI stage B and C cardiogenic shock...
2021: Clinical Medicine Insights. Cardiology